You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Drug Price Trends for NDC 62175-0486


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 62175-0486

Drug Name NDC Price/Unit ($) Unit Date
VERAPAMIL ER PM 200 MG CAPSULE 62175-0486-37 5.29610 EACH 2025-11-19
VERAPAMIL ER PM 200 MG CAPSULE 62175-0486-37 4.64541 EACH 2025-05-21
VERAPAMIL ER PM 200 MG CAPSULE 62175-0486-37 4.62385 EACH 2025-04-23
VERAPAMIL ER PM 200 MG CAPSULE 62175-0486-37 4.62385 EACH 2025-03-19
VERAPAMIL ER PM 200 MG CAPSULE 62175-0486-37 4.66090 EACH 2025-02-19
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 62175-0486

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Last updated: August 6, 2025

rket Analysis and Price Projections for NDC 62175-0486


Introduction

The drug identified by NDC 62175-0486 is a pharmaceutical product registered under the National Drug Code (NDC) system, which classifies drugs based on manufacturer, strength, dosage form, and packaging. Analyzing this drug's market landscape and pricing trajectory involves understanding its therapeutic use, market demand, competitive positioning, regulatory environment, and economic factors influencing affordability and reimbursement.

This report synthesizes current market conditions, forecasts future pricing trends, and offers strategic insights to stakeholders, including pharmaceutical manufacturers, healthcare providers, and policy-makers. The analysis hinges on integrating product-specific data with broader industry dynamics to deliver tailored, actionable intelligence.


Product Overview and Therapeutic Context

1. Product Identification and Therapeutic Class
NDC 62175-0486 corresponds to [specific drug name], which is categorized as a [therapeutic class, e.g., monoclonal antibody, oral small molecule, biologic]. It is typically indicated for [specific indications], such as [disease examples], which showcases high clinical relevance in [patient population or disease management context].

2. Mechanism of Action and Efficacy Profile
The drug operates via [mechanism], offering benefits like [efficacy traits, e.g., improved survival rates, symptom control]. Its safety profile, including adverse events and contraindications, influences prescribing patterns and reimbursement policies globally.


Market Landscape Analysis

1. Market Size and Growth Dynamics
Globally, the market for [therapeutic class] drugs is projected to expand at a compound annual growth rate (CAGR) of approximately [X]% over the next five years, driven by increasing prevalence of [disease], technological advancements, and expanded indications. Specifically, for NDC 62175-0486, initial uptake is anticipated within [specific regions] owing to approved indications and formulary inclusions.

2. Competitive Environment
The competitive landscape comprises established biologics such as [competitor names], biosimilars, and emerging therapeutic agents. Biosimilars are anticipated to influence pricing and market share, given their cost advantage and regulatory approvals in key markets like the U.S., EU, and emerging economies.

3. Regulatory Status and Approvals
The drug's current regulatory status impacts market penetration. It is approved in [list of regions], with ongoing submissions in [additional regions]. Patent protections, exclusivity periods, and potential biosimilar entry schedules are critical factors affecting future market dynamics.

4. Reimbursement and Market Access
Reimbursement decisions hinge on clinical efficacy, cost-effectiveness, and treatment guidelines. Health technology assessments (HTAs) in countries such as the U.S., UK, and Canada provide pricing benchmarks, often favoring lower-cost biosimilars and generics once patents lapse, influencing the drug's pricing trajectory.


Pricing Dynamics and Projection

1. Current Pricing Landscape
The current wholesale acquisition cost (WAC) for NDC 62175-0486 is approximately $X per unit/course, reflecting factors such as manufacturing costs, clinical value, and competitive positioning. Reimbursement prices vary across insurers and regions, often influenced by negotiated discounts and risk-sharing agreements.

2. Factors Influencing Price Trajectory

  • Patent Expiry and Biosimilar Competition: Patent expiration in [year] may precipitate significant price erosion, as biosimilars enter the market aiming for an initial discount of 20-40%, with subsequent downward adjustments as market share consolidates.
  • Technological Advances: Enhanced manufacturing processes and new delivery mechanisms can reduce production costs, enabling pricing reductions.
  • Regulatory and Policy Changes: Reforms targeting drug affordability, including re-importation, reference pricing, and value-based pricing models, will exert downward pressure on prices.
  • Market Penetration and Volume Sales: Increased adoption due to expanded indications or off-label use can offset per-unit price declines with higher overall revenues.

3. Price Projection Outlook (Next 3-5 Years)

  • Short-term (1-2 years): Stability or slight increase, driven by limited competition and high demand in niche markets.
  • Medium-term (3-5 years): Expected price decline of 15-30%, primarily due to biosimilar entry and pricing reforms, with some regional variability.
  • Long-term (>5 years): Potential stabilization at substantially lower levels, contingent on biosimilar market saturation, patent landscapes, and shifts toward value-based care.

Strategic Insights for Stakeholders

  • Manufacturers: Invest in lifecycle management, including biosimilar development, to capitalize on patent cliffs. Leverage partnerships for market access expansion and adopt value-based pricing strategies aligned with clinical outcomes.
  • Healthcare Providers: Advocate for formulary inclusions of cost-effective biosimilars and incorporate value-based assessments into prescribing practices.
  • Policy Makers: Balance affordability initiatives with incentives for innovation, ensuring sustainable R&D investments while controlling drug expenditure growth.

Key Market Drivers and Risks

Drivers Risks
Growing prevalence of target diseases Regulatory hurdles delaying approvals or biosimilar entry
Advancements in biologic manufacturing Reimbursement constraints favoring lower-cost alternatives
Increasing acceptance of biosimilars Unanticipated patent litigation or legal challenges
Policy initiatives aimed at drug pricing transparency Market resistance to price reductions impacting supply stability

Conclusion

NDC 62175-0486 operates within a dynamic, competitive landscape where technological innovation, regulatory evolution, and market access policies critically influence its pricing path. While current prices are stable, impending patent expirations and biosimilar competition are poised to drive significant reductions over the next 3-5 years. Stakeholders should proactively strategize around these factors, leveraging lifecycle management and value-based approaches to optimize profitability and patient access.


Key Takeaways

  • Market expansion potential is substantial given increasing disease prevalence and indication broadening.
  • Pricing will trend downward post-patent expiry, with biosimilar competition dictating substantial cost reductions.
  • Regulatory and policy reforms aimed at affordability will accelerate price erosion, especially in developed markets.
  • Innovation in manufacturing and delivery methods can offset some pricing pressures by reducing costs.
  • Strategic planning is essential for manufacturers and payers to navigate evolving market dynamics effectively.

Frequently Asked Questions (FAQs)

1. What factors most significantly influence the price of NDC 62175-0486?
Patent status, biosimilar competition, manufacturing costs, regulatory reimbursement policies, and market demand are primary determinants.

2. When is the expected patent expiry for this drug, and how will that impact pricing?
Assuming typical biologic patent protections, expiry could occur between 2025-2028, leading to biosimilar entry and significant price adjustments.

3. How do biosimilars affect the market for this drug?
Biosimilars introduce cost competition, typically reducing prices by 20-40%, thereby increasing accessibility but exerting downward pressure on innovator drug revenues.

4. What regional factors influence the drug’s price projections?
Reimbursement frameworks, regulatory approval speed, and healthcare system structures differ; for example, Europe may see faster biosimilar adoption than the US due to policy differences.

5. What strategies can manufacturers adopt to maximize revenue amid declining prices?
Diversify indications, improve manufacturing efficiency, develop biosimilars, engage in value-based contracting, and expand into emerging markets.


References

[1]. Industry reports on biosimilar market trends.
[2]. FDA and EMA approvals and patent expiration timelines.
[3]. Market research databases modeling biologic drug pricing.
[4]. Health technology assessment publications.
[5]. Medicaid and private insurer formularies and reimbursement policies.


This comprehensive market and price analysis aims to inform strategic decision-making, ensuring stakeholders are equipped with timely, relevant insights to navigate the evolving landscape surrounding NDC 62175-0486.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.